Agile Therapeutics Inc
OTC Pink - Current Information:AGRX

  • LAST PRICE
    0.3700
  • TODAY'S CHANGE (%)
    0.0022 (0.6118%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.3655 / 0.3678
  • Day Range
    0.3655
    0.3848
  • 52 Week Range
    0.2000
    7.4101
  • Volume
    15,137

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Mar 28, 2024

      Show headlines and story abstract

    • 8:06AM ET on Thursday Mar 28, 2024 by MT Newswires
      Companies Mentioned: AGRX
      08:06 AM EDT, 03/28/2024 (MT Newswires) -- ...

    • 8:06AM ET on Thursday Mar 28, 2024 by Dow Jones
      Companies Mentioned: AGRX
      --------- --------- Total liabilities 26,573 19,787 Stockholders' deficit Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2023 and no shares issued and outstanding at December 31, 2022 - - Common stock, $.0001 par value, 300,000,000 shares authorized, 2,963,657 and 859,402 issued and outstanding at December 31, 2023 and December 31, 2022, respectively 4 4 Additional paid-in capital 406,846 403,153 Accumulated deficit (423,168) (408,702) --------- --------- Total stockholders' deficit (16,318) (5,545) --------- --------- Total liabilities and stockholders' deficit $ 10,255 $ 14,242 ========= ========= Agile Therapeutics, Inc. Statement of Operations and Comprehensive Loss (in thousands, except share and per share data) Three Months Ended December 31, Year Ended (Unaudited) December 31, ------------------------- --------------------------- 2023 2022 2023 2022 Revenues, net $ 3,615 $ 3,996 $ 19,593 $ 10,884 Cost of product revenues 2,191 1,653 8,978 6,836 --------- ---------- --------- ---------- Gross profit 1,424 2,343 10,615 4,048 Operating expenses: Research and development $ 54 $ 352 $ 2,225 $ 3,253 Selling and marketing 3,729 6,844 17,769 30,369 General and administrative 1,691 2,023 10,505 11,860 Loss on disposition of assets - - - 11,122 --------- ---------- --------- ---------- Total operating expenses 5,474 9,219 30,499 56,604 --------- ---------- --------- ---------- Loss from operations (4,050) (6,876) (19,884) (52,556) Other income (expense) Interest income 17 30 78 80 Interest expense (304) (432) (1,419) (3,131) Unrealized (loss) gain on warrant liability (130) 3,349 6,760 25,520 --------- ---------- --------- ---------- Total other income (expense), net (417) 2,947 5,419 22,469 --------- ---------- --------- ---------- Loss before benefit from income taxes (4,467) (3,929) (14,465) (30,087) Benefit from income taxes - - - 4,675 --------- ---------- --------- ---------- Net loss $ (4,467) $ (3,929) $ (14,465) $ (25,412) ========= ========== ========= ========== Net loss per share (basic and diluted) $ (1.51) $ (0.10) $ (6.71) $ (1.18) ========= ========== ========= ========== Weighted-average common shares (basic and diluted) 2,963,657 41,232,562 2,156,726 21,610,947 ========= ========== ========= ========== Comprehensive loss: Net loss $ (4,467) $ (3,929) $ (14,465) $ (25,412) Other comprehensive income: Unrealized (loss) gain on marketable securities - - - - --------- ---------- --------- ---------- Comprehensive loss $ (4,467) $ (3,929) $ (14,465) $ (25,412) ========= ========== ========= ========== Agile Therapeutics, Inc. Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited) (in thousands) Three Months Ended Twelve Months Ended -------------------------------------------------------- ------------------------ 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 12/31/2023 12/31/2022 ---------- --------- --------- --------- ---------- ---------- ---------- GAAP Operating expenses $ 5,474 8,185 8,322 8,518 9,219 $ 30,499 $ 56,604 Non-GAAP adjustment: Loss on disposition of assets $ - - - - - $ - 11,122 ---------- --------- --------- --------- ---------- ---------- ---------- Non-GAAP operating expenses $ 5,474 8,185 8,322 8,518 9,219 $ 30,499 $ 45,482 ---------- --------- --------- --------- ---------- ---------- ---------- Agile Therapeutics, Inc. Unaudited Reconciliation of Net Loss (GAAP) to adjusted Net Loss (non-GAAP) (in thousands) Three Months Ended Twelve Months Ended ------------------------------------------------------------ -------------------------- 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 12/31/2023 12/31/2022 ---------- ---------- ---------- --------- ------------ ---------- ------------ GAAP Net Loss $ (4,467) (799) (3,809) (5,390) (3,929) $ (14,465) $ (25,412) Unrealized (loss) gain on warrant liability (130) 3,529 1,674 1,687 3,349 6,760 25,520 Loss on disposition of assets - - - - - - (11,122) --------- --------- --------- -------- -------- --------- -------- Non-GAAP Net Loss $ (4,337) (4,328) (5,483) (7,077) (7,278) $ (21,225) $ (39,810) --------- --------- --------- -------- -------- --------- -------- Non-GAAP Net Loss Per Share $ (1.46) (1.47) (3.10) (7.76) (8.82) $ (9.84) $ (92.15) ========= ========= ========= ======== ======== ========= ======== Weighted avg shares 2,963,657 2,950,136 1,769,803 912,044 824,651 2,156,726 432,219 --------- --------- --------- -------- -------- ---------

    • 8:05AM ET on Thursday Mar 28, 2024 by GlobeNewswire
      Companies Mentioned: AGRX

    • 8:05AM ET on Thursday Mar 28, 2024 by Dow Jones
      Companies Mentioned: AGRX

    • 8:05AM ET on Thursday Mar 28, 2024 by Dow Jones
      Companies Mentioned: AGRX
      --------- --------- Total liabilities 26,573 19,787 Stockholders' deficit Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2023 and no shares issued and outstanding at December 31, 2022 - - Common stock, $.0001 par value, 300,000,000 shares authorized, 2,963,657 and 859,402 issued and outstanding at December 31, 2023 and December 31, 2022, respectively 4 4 Additional paid-in capital 406,846 403,153 Accumulated deficit (423,168) (408,702) --------- --------- Total stockholders' deficit (16,318) (5,545) --------- --------- Total liabilities and stockholders' deficit $ 10,255 $ 14,242 ========= ========= Agile Therapeutics, Inc. Statement of Operations and Comprehensive Loss (in thousands, except share and per share data) Three Months Ended December 31, Year Ended (Unaudited) December 31, ------------------------- --------------------------- 2023 2022 2023 2022 Revenues, net $ 3,615 $ 3,996 $ 19,593 $ 10,884 Cost of product revenues 2,191 1,653 8,978 6,836 --------- ---------- --------- ---------- Gross profit 1,424 2,343 10,615 4,048 Operating expenses: Research and development $ 54 $ 352 $ 2,225 $ 3,253 Selling and marketing 3,729 6,844 17,769 30,369 General and administrative 1,691 2,023 10,505 11,860 Loss on disposition of assets - - - 11,122 --------- ---------- --------- ---------- Total operating expenses 5,474 9,219 30,499 56,604 --------- ---------- --------- ---------- Loss from operations (4,050) (6,876) (19,884) (52,556) Other income (expense) Interest income 17 30 78 80 Interest expense (304) (432) (1,419) (3,131) Unrealized (loss) gain on warrant liability (130) 3,349 6,760 25,520 --------- ---------- --------- ---------- Total other income (expense), net (417) 2,947 5,419 22,469 --------- ---------- --------- ---------- Loss before benefit from income taxes (4,467) (3,929) (14,465) (30,087) Benefit from income taxes - - - 4,675 --------- ---------- --------- ---------- Net loss $ (4,467) $ (3,929) $ (14,465) $ (25,412) ========= ========== ========= ========== Net loss per share (basic and diluted) $ (1.51) $ (0.10) $ (6.71) $ (1.18) ========= ========== ========= ========== Weighted-average common shares (basic and diluted) 2,963,657 41,232,562 2,156,726 21,610,947 ========= ========== ========= ========== Comprehensive loss: Net loss $ (4,467) $ (3,929) $ (14,465) $ (25,412) Other comprehensive income: Unrealized (loss) gain on marketable securities - - - - --------- ---------- --------- ---------- Comprehensive loss $ (4,467) $ (3,929) $ (14,465) $ (25,412) ========= ========== ========= ========== Agile Therapeutics, Inc. Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited) (in thousands) Three Months Ended Twelve Months Ended -------------------------------------------------------- ------------------------ 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 12/31/2023 12/31/2022 ---------- --------- --------- --------- ---------- ---------- ---------- GAAP Operating expenses $ 5,474 8,185 8,322 8,518 9,219 $ 30,499 $ 56,604 Non-GAAP adjustment: Loss on disposition of assets $ - - - - - $ - 11,122 ---------- --------- --------- --------- ---------- ---------- ---------- Non-GAAP operating expenses $ 5,474 8,185 8,322 8,518 9,219 $ 30,499 $ 45,482 ---------- --------- --------- --------- ---------- ---------- ---------- Agile Therapeutics, Inc. Unaudited Reconciliation of Net Loss (GAAP) to adjusted Net Loss (non-GAAP) (in thousands) Three Months Ended Twelve Months Ended ------------------------------------------------------------ -------------------------- 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 12/31/2023 12/31/2022 ---------- ---------- ---------- --------- ------------ ---------- ------------ GAAP Net Loss $ (4,467) (799) (3,809) (5,390) (3,929) $ (14,465) $ (25,412) Unrealized (loss) gain on warrant liability (130) 3,529 1,674 1,687 3,349 6,760 25,520 Loss on disposition of assets - - - - - - (11,122) --------- --------- --------- -------- -------- --------- -------- Non-GAAP Net Loss $ (4,337) (4,328) (5,483) (7,077) (7,278) $ (21,225) $ (39,810) --------- --------- --------- -------- -------- --------- -------- Non-GAAP Net Loss Per Share $ (1.46) (1.47) (3.10) (7.76) (8.82) $ (9.84) $ (92.15) ========= ========= ========= ======== ======== ========= ======== Weighted avg shares 2,963,657 2,950,136 1,769,803 912,044 824,651 2,156,726 432,219 --------- --------- --------- -------- -------- --------- --------

Peers Headlines